Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Abstract Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant...

Full description

Bibliographic Details
Main Authors: Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Experimental Hematology & Oncology
Subjects:
Cell-free DNA
cfDNA
Genomic evolution
Acquired resistance
Osimertinib
Guardant360
Online Access:http://link.springer.com/article/10.1186/s40164-019-0148-7

Internet

http://link.springer.com/article/10.1186/s40164-019-0148-7

Similar Items